

**Enantioselective Syntheses of *Monomorium minutum* Ant Venom Alkaloids :
 (5R)-2-(5-Hexenyl)-5-nonyl-3,4-dihydro-2H-pyrrole and (2R,5R)-2-(5-Hexenyl)-5-nonylpyrrolidine
 from (S)-pyroglutamic acid.**



S. Rosset, J.P. C  lerier, and G. Lhommet*

Universit   Pierre et Marie Curie. Laboratoire de Chimie des H  t  rocycles, associ   au CNRS.
 4 Place Jussieu. 75252 Paris cedex 05 France.

Key Words : (S)-pyroglutamic acid; cyclic imine formations; cyclic imine reductions.

Abstract : We describe enantioselective syntheses of 2,5-disubstituted pyrroline and pyrrolidine with unsaturated radical, starting from (S)-pyroglutamic acid.

2,5-Disubstituted pyrrolines and pyrrolidines characterize a large family of naturally occurring alkaloids, many of which display significant biological activity^{1,2}. Termites in the genus *Reticulitermes* represent the largest source of food of ants in the genus *Monomorium*. When killing their prey, ants use a paralyzing venom. The analysis of the chemical composition of the venom of european *Monomorium minutum* species and the determination of the quantity of each separate constituent were achieved using coupled GC-MS³. Three *trans*-pyrrolidines (**1 a,b,c**), and two pyrrolines (**2 a,b**) were detected. Their absolute configurations have not been yet established, owing to the scarcity of the natural material.




a ; R¹ = (CH₂)₇-CH=CH₂, R² = (CH₂)₄-CH=CH₂

b ; R¹ = n-C₉H₁₉, R² = (CH₂)₄-CH=CH₂

c ; R¹ = n-C₉H₁₉, R² = n-C₆H₁₃


Alkaloid	% in venom
1a	30
1b	59
1c	2
2a	5
2b	4

We have now developed general routes to optically active *trans*-2,5-dialkylated pyrrolidines and pyrrolines, especially with unsaturated substituents^{4,5}. Our retrosynthetic approach includes the reduction of natural **2**, or unnatural **3** pyrrolines, starting from a readily available amino acid : (S)-pyroglutamic acid.



In this paper we describe the enantioselective preparations of the enantiomer (2R,5R)-2-(5-hexenyl)-5-nonyl-pyrrolidine **1b** which is the most important component of the venom and its biological precursor the (5R)-pyrroline **2b**. The two strategies reported introduce the nonyl substituent either

from the tosylate **2e**, or from the thiolactim ether **3g** (Scheme 1), to prepare respectively the natural (2R)-2-(5-hexenyl)-5-nonyl-3,4-dihydro-2H-pyrrole **2b** (Route A - Scheme 2), and the 5-hydroxymethyl cyclic imine **3h** (Route B - Scheme 3).




Reagents : (i) MeOH, SOCl₂; (ii) NaBH₄, EtOH; (iii) TsCl, N(Et)₃; (iv) [n-C₈H₁₇]₂CuLi; (v) Et₃OBF₄, CH₂Cl₂; (vi) Ac₂O, pyridine; (vii) Lawesson's reagent; (viii) CH₃I, then MeONa-MeOH.

Scheme 1

Route A : Syntheses of natural pyrroline **2b and pyrrolidine **1b**.**

(S)-Pyroglutamic acid is esterified, reduced, then the resulting alcohol **2d** is converted into the tosylate **2e**⁶. Lithium dioctyl cuprate reacts with compound **2e** to give (R)-5-nonylpyrrolidinone **2f** in 80% yield [α]_D²² +9 (c=0.91, EtOH). Lactim ether **2g** is prepared by reaction of lactam **2f** with Meerwein's salt (Et₃OBF₄) (Scheme 1), then condensed with isopropylidene malonate in chloroform with a catalytic amount of Ni(acac)₂ to give compound **5** in 84% yield [α]_D²² +17 (c=0.87, CHCl₃). A monodecarboxylating transesterification of β -enamino diester **5**, in EtOH at 230°C for 30 minutes leads to the (5R)-Z-ethyl (5-nonyl-2-tetrahydropyrrolidinylidene) acetate **6a** in 74% yield [α]_D²² -20 (c=2.12, CHCl₃). Afterwards the sodium salt of **6a** is generated by action of sodium hydride in toluene, then alkylated with 1-bromo-4-pentene leading to the C-alkylated β -enamino ester **6b** which is already decarboxylated using boric acid at 200°C to give the natural imine **2b**⁷ in 30% yield (2 steps), [α]_D¹⁹ +36 (c=1.55, CHCl₃) (Scheme 2).



Reagents : (i) Meldrum's acid, Ni(acac)₂, CHCl₃; (ii) EtOH, 230°C; (iii) NaH, Br-(CH₂)₃CH=CH₂, toluene; (iv) H₃BO₃, 200°C; (v) NaBH₄, AcOH.


Scheme 2

Chemical reduction of imine **2b** with sodium borohydride in acetic acid leads to a mixture of *trans* and *cis*-pyrrolidines **1b** and **7b** (ratio 65/35 established by ^{13}C -NMR⁸) which is difficult to separate.

In continuation of our work on the synthesis of optically *trans*-2,5-dialkylated pyrrolidines we have developed a second strategy where we expected to provide better selectivity towards the reduction of imines and easier separation of pyrrolidines diastereoisomers.

Route B : Second synthesis of pyrrolidine **1b.**

The alcohol **2d**, resulting from the reduction of pyroglutamic acid is acetylated (Ac_2O -pyridine) to give the acetate **3e**, then followed by Lawesson's treatment, the crystalline thiolactam **3f** is obtained in 80% yield. Reaction of **3f** with methyl iodide in methylene chloride at room temperature followed by a sodium methoxide in methanol reaction gives the thioimide **3g**⁹ (Scheme 1). Then nonylmagnesium bromide reacts with thiolactim ether **3g** to lead to (*S*)-imino alcohol **3h** in 75% yield $[\alpha]_D^{20} +68$ ($c=1.35$, CHCl_3). Reduction of imine **3h** using $\text{NaBH}(\text{OAc})_3$ in toluene leads to a mixture of *trans* and *cis*-hydroxymethylpyrrolidines **1d** and **7d** (ratio 70/30 determined by G.C.) in 95% yield, followed by reaction with benzyl chloroformate at room temperature gives a mixture of carbamates **1e** and **7e**, a flash chromatography permits to isolate the pure *trans*-carbamate **1e** in 45% yield $[\alpha]_D^{20} -41$ ($c=1.08$, CHCl_3). The benzyl methylene protons of compound **1e** appear as a well-resolved AB quartet consistent with a *trans* disposition of the two alkyl groups in which the methylene protons are nonequivalent. The *trans* carbamate **1e** is converted into the tosylate **1f** in 70% yield $[\alpha]_D^{20} -30$ ($c=1.04$, CHCl_3), and reacts with lithium dipentenyl cuprate to afford the pyrrolidine carbamate **1g** in 91% yield $[\alpha]_D^{20} -50$ ($c=0.97$, CHCl_3). Finally, treatment of **1g** with Me_3SiI gives the natural *trans* pyrrolidine **1b** in 66% yield $[\alpha]_D^{20} -3$ ($c=0.8$, MeOH) (Scheme 3).



Reagents : (i) $n\text{-C}_9\text{H}_{19}\text{MgBr}$, ether- CH_2Cl_2 ; (ii) $\text{NaBH}(\text{OAc})_3$, toluene; (iii) CBzCl , NaHCO_3 , H_2O ; (iv) TsCl , pyridine; (v) $[\text{CH}_2=\text{CH}(\text{CH}_2)_3]_2\text{CuLi}$; (vi) Me_3SiI , CHCl_3 .

Scheme 3

The diastereoisomeric excess observed for the pyrrolidine formation may be attributed to the participation of the hydroxy group which directs delivery of hydride ion from the *si*-face of the imino group by forming a boronate complex¹⁰ to give the *trans*-2,5-dialkylpyrrolidine **1d**.

In conclusion, we describe the first enantioselective synthesis of 2,5-disubstituted pyrroline with a terminal double bond and the second preparation of optically active *trans*-2,5 disubstituted pyrrolidine with an unsaturated substituent which will permit, in the future, to establish the absolute configurations of the natural products.

Aknowledgment : We are grateful to E.I. Dupont de Nemours, Wilmington for financial support and thank U.C.I.B. (Usines Chimiques d'Ivry-la-Bataille-France) for the generous gift of (S)-pyroglutamic acid.

References

1. Jones, T.H.; Blum, M.S.; Escoubas, P.; Musthak Ali, T.M. *J. Nat. Products* **1989**, *52*, 779.
2. Cassier, P.; Lemaire, M.; Clément, J.L.; Basselier, J.J.; Lange, C.; Célérier, J.P.; Lhommet, G. *French Patent n° 84/06980*; *Chem. Abstr.* **1986**, *104*, 20233.
3. Lange, C.; Célérier, J.P.; Lhommet, G.; Basselier, J.J.; Lemaire, M.; Escoubas, P.; Clément, J.L.; *Biomedical Environment Mass Spectroscopy* **1989**, *18*, 780.
4. For recent syntheses of racemic *trans*-2,5-dialkylpyrrolidine alkaloids, see : (a) Tufariello, J.J.; Pieglis, J.M. *Tetrahedron Lett.* **1986**, *27*, 1489. (b) Gessner, W.; Takahashi, K.; Brossi, A.; Kowalski, M.; Kaliner, M.A. *Helv. Chim. Acta* **1987**, *70*, 2003. (c) Miyashita, M.; Awen, B.Z.E., Yoshikoshi, A. *Chem. Lett.* **1990**, 239. (d) Bäckvall, J.E.; Schiuk, H.E.; Renko, Z.D. *J. Org. Chem.* **1990**, *55*, 826.
5. For the syntheses of optically active *trans* 2,5 dialkylpyrrolidine alkaloids, see : (a) Shiosaki, K.; Rapoport, H. *J. Org. Chem.* **1985**, *50*, 1229. (b) Huang, P.Q.; Arseniyadis, S.; Husson, H.P. *Tetrahedron Lett.* **1987**, *28*, 547. (c) Jegham, S.; Das, B.C. *Tetrahedron Lett.* **1989**, *30*, 2801. (d) Takahata, H.; Takehara, H.; Ohkubo, N.; Momose, T. *Tetrahedron Asymetry* **1990**, *1*, 561. (e) Machinaga, N.; Kibayashi, C. *J. Org. Chem.* **1991**, *56*, 1386. (f) Wistrand, L.G.; Skrinjar, M. *Tetrahedron* **1991**, *47*, 573.
6. Smith, A.L.; Williams, S.F.; Holmes, A.B. *J. Am. Chem. Soc.* **1988**, *110*, 8696.
7. For a synthesis of racemic **2b**, see : Bacos, D.; Basselier, J.J.; Célérier, J.P.; Lange, C.; Marx, E.; Lhommet, G.; Escoubas, P.; Lemaire, M.; Clément, J.L. *Tetrahedron Lett.* **1988**, *29*, 3061.
8. Bacos, D.; Célérier, J.P.; Marx, E.; Rosset, S.; Lhommet, G. *J. Heterocyclic Chem.* **1990**, *27*, 1387.
9. Attempted synthesis of *trans*-pyrrolidines from (S)-pyroglutamic acid, See : Marco, J.L. *J. Heterocyclic Chem.* **1986**, *23*, 1059.
10. Takano, S.; Otaki, S.; Ogasawara, K. *J. Chem. Soc., Chem. Commun.* **1983**, 1172.

(Received in France 26 July 1991)